Refametinib (BioDeep_00000772288)
代谢物信息卡片
化学式: C19H20F3IN2O5S (572.0089736)
中文名称: Refametinib
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)CC(CO)O)NC3=C(C=C(C=C3)I)F)F)F
InChI: InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1
描述信息
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C69145 - Mitogen-Activated Protein Kinase Kinase Inhibitor
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric MEK1/MEK2 inhibitor with IC50s of 19 nM and 47 nM, respectively.
同义名列表
3 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- PubChem: 44182295
- DrugBank: DB06309
- ChEMBL: CHEMBL1236682
- CAS: 923032-36-4
- CAS: 923032-37-5
- medchemexpress: HY-14691
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jean-Luc Van Laethem, Hanno Riess, Jacek Jassem, Michael Haas, Uwe M Martens, Colin Weekes, Marc Peeters, Paul Ross, John Bridgewater, Bohuslav Melichar, Stefano Cascinu, Piotr Saramak, Patrick Michl, David Van Brummelen, Alberto Zaniboni, Wollf Schmiegel, Svein Dueland, Marius Giurescu, Vittorio L Garosi, Katrin Roth, Anke Schulz, Henrik Seidel, Prabhu Rajagopalan, Michael Teufel, Barrett H Childs. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Targeted oncology.
2017 02; 12(1):97-109. doi:
10.1007/s11523-016-0469-y. [PMID: 27975152] - Alex A Adjei, Donald A Richards, Anthony El-Khoueiry, Fadi Braiteh, Carlos H R Becerra, Joe J Stephenson, Aram F Hezel, Morris Sherman, Lawrence Garbo, Diane P Leffingwell, Cory Iverson, Jeffrey N Miner, Zancong Shen, Li-Tain Yeh, Sonny Gunawan, David M Wilson, Kimberly J Manhard, Prabhu Rajagopalan, Heiko Krissel, Neil J Clendeninn. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016 05; 22(10):2368-76. doi:
10.1158/1078-0432.ccr-15-1681. [PMID: 26644411] - Roberta Schmieder, Florian Puehler, Roland Neuhaus, Maria Kissel, Alex A Adjei, Jeffrey N Miner, Dominik Mumberg, Karl Ziegelbauer, Arne Scholz. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Neoplasia (New York, N.Y.).
2013 Oct; 15(10):1161-71. doi:
10.1593/neo.13812. [PMID: 24204195] - Colin D Weekes, Daniel D Von Hoff, Alex A Adjei, Diane P Leffingwell, S Gail Eckhardt, Lia Gore, Karl D Lewis, Glen J Weiss, Ramesh K Ramanathan, Grace K Dy, Wen W Ma, Beth Sheedy, Cory Iverson, Jeffrey N Miner, Zancong Shen, Li-Tain Yeh, Ronald L Dubowy, Michael Jeffers, Prabhu Rajagopalan, Neil J Clendeninn. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Mar; 19(5):1232-43. doi:
10.1158/1078-0432.ccr-12-3529. [PMID: 23434733] - Tobias M Gorges, Johanna Schiller, Arndt Schmitz, Daniel Schuetzmann, Christoph Schatz, Thomas M Zollner, Thomas Krahn, Oliver von Ahsen. Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
2012 Sep; 17(6):498-506. doi:
10.3109/1354750x.2012.689133. [PMID: 22616911] - Qing Chang, Mark S Chapman, Jeffrey N Miner, David W Hedley. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
BMC cancer.
2010 Sep; 10(?):515. doi:
10.1186/1471-2407-10-515. [PMID: 20920162]